Galcanezumab reduces trigeminal nociception and is effective in preclinical models of migraine and trigeminal autonomic cephalalgias
Galcanezumab likely acts via a shared trigeminovascular mechanism to dampen noxious and nonnoxious sensory stimuli in preclinical models of migraine and trigeminal autonomic cephalalgias. This further supports the clinical efficacy of galcanezumab for migraine and cluster headache, while demonstrating general inhibition that may be of relevance to other facial pain conditions.
Authors
- Peter J. Goadsby (ORCID: https://orcid.org/0000-0003-3260-5904)
- Philip R. Holland (ORCID: https://orcid.org/0000-0003-3345-4853)
- Marta Vila‐Pueyo (ORCID: https://orcid.org/0000-0003-0652-2988)
- Kirk W. Johnson (ORCID: https://orcid.org/0000-0003-0849-508X)
Institutions
- Eli Lilly (United States) (US)
- King's College London (GB)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-07-21
- DOI
- https://doi.org/10.1111/head.15006
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Eli Lilly and Company